Hetal H. Mehta, MD, FACC, FSCAI (@DocMehta407) header
Hetal H. Mehta, MD, FACC, FSCAI (@DocMehta407) profile picture

Interventional/Structural Cardiologist @DoylestownHlth, former @yalecardiology structural fellow, @hopkinsheart IC fellow, @TJheartfellows. Tweets are my own.

Doylestown, PA
Joined December 2017
Photo by Hetal H. Mehta, MD, FACC, FSCAI (@DocMehta407)Photo by Hetal H. Mehta, MD, FACC, FSCAI (@DocMehta407)Photo by Hetal H. Mehta, MD, FACC, FSCAI (@DocMehta407)Photo by Hetal H. Mehta, MD, FACC, FSCAI (@DocMehta407)Photo by Hetal H. Mehta, MD, FACC, FSCAI (@DocMehta407)Photo by Hetal H. Mehta, MD, FACC, FSCAI (@DocMehta407)Photo by Hetal H. Mehta, MD, FACC, FSCAI (@DocMehta407)Photo by Hetal H. Mehta, MD, FACC, FSCAI (@DocMehta407)Photo by Hetal H. Mehta, MD, FACC, FSCAI (@DocMehta407)Photo by Hetal H. Mehta, MD, FACC, FSCAI (@DocMehta407)
Our 1000th TAVR! So proud of our amazing team!! @DoylestownHlth
1
49
3,838
Hetal H. Mehta, MD, FACC, FSCAI retweeted
.@Drroxmehran calls for an interventional cardiology culture where women can thrive, free from bias and outdated barriers, with equal pathways to leadership. Her message: pursue your dreams, know your worth and never accept mistreatment. pcronline.com/Cases-resource…
11
24
764
Hetal H. Mehta, MD, FACC, FSCAI retweeted
🫀 New #JACCINT: #TAVR vs #SAVR for isolated native #AR! 🏥 TAVR offered shorter stays and similar 5-year survival, but more pacemakers⚡and repeat valve interventions 🔄. Important real-world comparative data! 📊 bit.ly/4ztHRyv
22
68
6,047
Hetal H. Mehta, MD, FACC, FSCAI retweeted
In patients undergoing TAVI, this meta-analysis of randomised trials suggested that routine PCI reduced MACE and unplanned revascularisation at the expense of increased major bleeding. Physiology-guided PCI was associated with the most favourable efficacy profile among the strategies evaluated. 🔗eurointervention.pcronline.c… @KamilBujak12 @DanieleGiacoppo @LaudaniClaudio @marcospagnolo21 @mariasaramauro @giacinto_dileo @Sim_Finocchiaro @AGrecoMD @DFCapodanno #TAVI #PCI #CoronaryArteryDisease
1
20
2
31
3,900
When you’re one of the few, 2.2% hits differently As a woman performing TAVR & M-TEER in community practice, this resonates deeply Grateful for our team @DoylestownHlth May these statistics become history for the next generation! doi.org/10.1016/j.jscai.2026… #WIC #StructuralHeart
2
7
523
Hetal H. Mehta, MD, FACC, FSCAI retweeted
🧵 1) @CMSGov TAVR NCD released yesterday! Big policy news in the cardiovascular space. Summary in the graphic. But let’s talk winners and losers in this thread.
3
20
63
7,928
Hetal H. Mehta, MD, FACC, FSCAI retweeted
Amanda Randles, PhD, describes the scientific foundations of two trials comparing how noninvasive and invasive assessments of fractional flow reserve affect clinical outcomes. Learn more about the science behind the study: nej.md/4xUKlGx
4
80
5
309
41,404
Hetal H. Mehta, MD, FACC, FSCAI retweeted
The updated 2026 AHA/ACC Clinical Performance & Quality Measures for Patients with #AFib address in-hospital & continuing outpatient care, including Class 1 & Class 3 guideline-recommended processes. Get the full details in #JACC: jacc.org/doi/10.1016/j.jacc.…
2
17
41
8,503
Hetal H. Mehta, MD, FACC, FSCAI retweeted
Does a 0 calcium score mean you can skip the statin? This MESA study takes a closer look at how CAC may refine statin decisions in the PREVENT era. jacc.org/doi/10.1016/j.jacc.… #JACC #cvPrev #ASCVD
5
76
8
218
39,877
Hetal H. Mehta, MD, FACC, FSCAI retweeted
Clopidogrel, ticagrelor or prasugrel after PCI? A question every operator answers daily. A new systematic review and network meta-analysis in JAMA Cardiology (1 July 2026) pools 15 randomised trials and 48,904 patients to rank the three oral P2Y12 inhibitors. 1/7
4
36
1
122
21,083
Hetal H. Mehta, MD, FACC, FSCAI retweeted
A new anchoring approach could help address challenging #TAVR cases involving pure aortic regurgitation and an enlarged LVOT. A recent case report describes the modified NCPI-plus technique and its potential application in this complex anatomy. Read more ➡️ cardiovascularbusiness.com/t… #InterventionalCardiology @CardioBusiness
9
24
4,333
Hetal H. Mehta, MD, FACC, FSCAI retweeted
CLASP-IID trial: For patients with suboptimal mitral #TEER results, those with MR ≤1+ & mean gradient >5 mmHg had better 1-yr prognosis than MR ≥2+ & gradient ≤5 mmHg. Favors optimizing MR over preserving lower gradient. jacc.org/doi/10.1016/j.jcmg.… #JACCIMG #vhdMR @AkhilNarangMD
11
1
37
6,864
Hetal H. Mehta, MD, FACC, FSCAI retweeted
Slow flow and no reflow remain major unresolved challenges after PCI, particularly in STEMI. Discover our State-of-the-Art review by @sbrugaletta et al exploring the mechanisms, diagnosis, and current treatment strategies eurointervention.pcronline.c… #STEMI #PCI #NoReflow #InterventionalCardiology
2
78
2
191
16,983
Hetal H. Mehta, MD, FACC, FSCAI retweeted
Complete revasc (CR) in pts with non-shock STEMI and multivessel ds. reduces MACE. But is the best timing for non-culprit lsn PCI immediate (during primary PCI) or staged? Our new meta-analysis publ in Circ CV Interv suggests immediate CR may increase mortality, same as in shock.
10
87
3
256
35,277
Hetal H. Mehta, MD, FACC, FSCAI retweeted
Congratulations to the #SCAI2026 30 in Their 30s recipients—highlighting the next generation of leaders advancing interventional cardiology through clinical excellence, research, and mentorship. 🌟👩‍⚕️👨‍⚕️ Learn more ➡️ scai.org/media-center/news-a… @Dr_AbuDaya @ZaidAlMarzooq @Obadah1Md @nyalborgesmd @BhattadMD @YChowdhuryMD @DocEBROhimi @fangjonathanx @HarmanSGill @KIgbalode @AhmadJabri8 @vikjag45 @ikutkutMD @NinoNJ @MukarramOsama @DrPrimeroNg @BhavanPentaMD @haseebqazi @frahman480 @sumonroy_md @drsharmatoishi @Tabaza @BWanamakerMD @ATYounesMD @JDawnAbbott1 @CCAD_MHIF @MHIF_Heart
3
11
6
37
12,517
Thrilled to welcome the Pascal platform to our structural heart program @DoylestownHlth @PennMedicine Expanding our toolkit means more options, more precision & more patients getting the care they deserve. Proud of the excellent outcomes we continue to achieve with every M-TEER🫀
1
184
Hetal H. Mehta, MD, FACC, FSCAI retweeted
After TAVI, invasively measured transvalvular gradients—but not echocardiography-derived gradients— were associated with mortality up to 2 years. Echocardiography systematically overestimated gradients, particularly with balloon-expandable valves. Read more in our #EIJBestOf 👇 #CardioTwitter #TAVI 🔗eurointervention.pcronline.c… @RikAdrMD @verhemel @Rjnuis @JoostDaemen @drnvanmieghem
64
126
10,379
Hospital-level variability in NSTEMI management and outcomes @CRT_meeting #CRT2026
2
123
Hetal H. Mehta, MD, FACC, FSCAI retweeted
New State-of-the-Art: lesion stratification with intracoronary imaging, from morphology-guided PCI to AI-enabled morphofunctional assessment, outlining the next paradigm shift in interventional cardiology. #InterventionalCardiology #IntracoronaryImaging eurointervention.pcronline.c… @m_g_mcgarvey @K_DeSilva @DrKeeble @DrPeterOKane @ziadalinyc @divaka_perera @DrJMHill @DrNileshPareek
1
38
101
5,746
Hetal H. Mehta, MD, FACC, FSCAI retweeted
LAA closure – is peri-device patency a problem to address? This pooled meta-analysis reveals that residual LAA patency detected by cardiac CT post-#LAAO significantly raises thromboembolic risk. jacc.org/doi/10.1016/j.jcmg.… #JACCIMG @KasperKorsholm @XanderJacquemyn @IbrahimSultanMD
1
19
67
7,571